Elpis Biopharmaceuticals

We are developing bispecific antibodies to overcome this therapeutic challenge. We are conducting animal studies to understand its mechanism of action and tumor killing efficacy. Cancer is a heterogeneous disease whose pathogenesis is often driven by multiple signaling pathways or genetic alterations which evolve with treatment and metastasis. EPIM-001 is the leading immuno-modulator drug candidate for various solid tumors. Adoptive cell therapy is a rapidly emerging immunotherapeutic in which a patient’s own immune cells are engineered to fight against their cancer cells. To combat tumor antigen loss and subsequent tumor escape, we are developing next generation CAR-T cell therapeutics that target two or more tumor specific/associated antigens simultaneously.